Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

Documenti analoghi

• Simulated cost‐effectiveness of a novel precision‐guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy
  di: Elmar R. Alizadeh, et al.
  Pubblicazione: (2024)
• Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
  di: Remo Panaccione
  Pubblicazione: (2024)
• Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure
  di: Julian Panés, et al.
  Pubblicazione: (2024)
• To give or not give corticosteroids; that is the question
  di: Claire E. Ciarkowski, et al.
  Pubblicazione: (2024)
• A re‐assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight
  di: Pedro Mercader‐García, et al.
  Pubblicazione: (2024)